Life Expectancy in Patients with Hepatitis C-Related Cirrhosis Who Achieve Sustained Virologic Response
MAY 10, 2016
A patient is generally considered cured of hepatitis C if he or she undergoes treatment and achieves sustained virologic response, an indication that the virus is no longer detected in the blood.
To further investigate the survival benefits of reaching SVR, researchers looked at prospective surveillance data from tertiary liver centers of three independent cohorts of Italian patients who had compensated hepatitis C virus-related cirrhosis. They compared patients who achieved SVR after being treated with interferon-based therapy with non-SVR treated and untreated patients.
Out of roughly 1,800 patients who had hepatitis C-related cirrhosis, 795 were given interferon-based antiviral drugs and 181 achieved SVR, the news release stated. Of those who achieved SVR, the survival rate was slightly above 90% at the 10-year mark and 63% at 20 years, similar to that of the sex-and age-matched general population, according to the article.
"These results confirm that patients who respond well to interferon-based therapies have a similar life expectancy to the general population, and suggest that treatment should be given as early as possible to patients with compensated HCV cirrhosis in order to achieve the highest benefit," Bruno said in the release.
"Availability of interferon-free new direct antiviral agents (DAA) regimens will allow even sicker patients and those ineligible for interferon to achieve SVR, a major advance given that the mortality rate of these patients is extremely high in comparison to the general population. However, the overall impact of SVR needs to be assessed in further dedicated studies," Bruno concluded.